Please provide your email address to receive an email when new articles are posted on . Administering a once-yearly infusion of zoledronic acid within 90 days after the surgical repair of a low-trauma ...

Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

To earn CME related to this news article, click here. April 20, 2009 — A single 5-mg intravenous infusion of zoledronic acid was at least as effective and more acceptable to patients than 5 mg of oral ...

June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...

Comparison of Diameter and Perimeter Methods for Tumor Volume Calculation PURPOSE: Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to ...

(HealthDay News) – For men with osteoporosis, a once-yearly infusion with zoledronic acid is associated with fewer vertebral fractures and improved bone health compared with placebo, according to a ...

Zoledronic acid, while a bisphosphonate itself, is much more potent, and needs only to be given in a once-yearly infusion. In this randomised controlled trial, Professor David M Reid, University of ...

A single infusion of zoledronic acid reduces fracture risk for more than 1 year, new data suggest. Annual infusions of zoledronic acid reduce fracture risk in postmenopausal women with osteoporosis.

Paracetamol taken for 3 days reduces post-dose symptoms related to zoledronic acid infusion, new research reveals. Transient post-dose symptoms, including fever and myalgia, may occur following the ...